Catalog Products » LRIG1, His, Human
Manual
Manual
COAs

LRIG1, His, Human

The leucine-rich repeats and immunoglobulin-like domains (LRIG)-1 is a tumor suppressor gene that belongs to the LRIG family. LRIG1 expression has prognostic significance in various human cancers. Somatic mutations, which are associated with a certain rate of response to targeted therapies, are ubiquitously found in human non-small cell lung cancer (NSCLC). LRIG1 was an independent prognostic factor for OS of NSCLC patients. LRIG1 in combination with other clinicopathological risk factors was a stronger prognostic model than clinicopathological risk factors alone.
$390.00
Z05608-100

Ask us a question
Product Introduction
Species Human
Protein Construction
LRIG1 (Ala35-Ser779)_x000D_
Accession # Q96JA1-1		 His
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 83 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 85-105 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in 50mM MES, 150mM NaCl, 1mM EDTA (pH 5.0).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in 50mM MES, 150mM NaCl, 1mM EDTA (pH 5.0).
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.
Back

LRIG1, His, Human

Immobilized LRIG1, His, Human, His Tag at 2 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-LRIG1 Antibody, hFc Tag with the EC50 of 3.6ng/ml determined by ELISA. »

LRIG1, His, Human

LRIG1, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

<
>

Background
Target Background The leucine-rich repeats and immunoglobulin-like domains (LRIG)-1 is a tumor suppressor gene that belongs to the LRIG family. LRIG1 expression has prognostic significance in various human cancers. Somatic mutations, which are associated with a certain rate of response to targeted therapies, are ubiquitously found in human non-small cell lung cancer (NSCLC). LRIG1 was an independent prognostic factor for OS of NSCLC patients. LRIG1 in combination with other clinicopathological risk factors was a stronger prognostic model than clinicopathological risk factors alone.
Synonyms LIG-1; LIG1; LRIG1; D6Bwg0781e; Img
Back

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.